Publications

Publications on NASH Cirrhosis

Chalasani N, Abdelmalek MF, Garcia-Tsao G, Vuppalanchi R, Alkhouri N, Rinella M, Noureddin M, Pyko M, Shiffman M, Sanyal A, Allgood A, Shlevin H, Horton R, Zomer E, Irish W, Goodman Z, Harrison SA, Traber PG (2020) Effects of Belapectin, an Inhibitor of Galectin-3, in Patients with Nonalcoholic Steatohepatitis With Cirrhosis And Portal Hypertension. Gastroenterology S0016-5085(19)41895-7. doi.org/10.1053/j.gastro.2019.11.296
Download PDF >

Shamseddeen H, Vilar‑Gomez E, Chalasani N, Myers RP, Subramanian GM, Shlevin HH, Allgood AE, Orman ES (2020) Spontaneous Fluctuations in Liver Biochemistries in Patients with Compensated NASH Cirrhosis: Implications for Drug Hepatotoxicity Monitoring. Drug Safety 43:281–290. doi.org/10.1007/s40264-019-00896-1
Download PDF >

Harrison SA, Dennis A, Fiore MM, Kelly MD, Kelly CJ, Paredes AH, et al. (2018) Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial. PLoS ONE 13(9): e0203054. https://doi.org/10.1371/journal.pone.0203054
Download PDF >

Harrison SA, Marri SR, Chalasani N, Kohli R, Aronstein W, Thompson GA, Irish W, Miles MV, Xanthakos SA, Lawitz E, Noureddin M, Schiano TD, Siddiqui M, Sanyal A, Neuschwander-Tetri BA, Traber PG (2016) Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis. Aliment Pharmacol Ther 44: 1183–1198. https://doi:10.1111/apt.13816
Download PDF >

Traber PG, Chou H, Zomer E, Hong F, Klyosov A, et al. (2013) Regression of Fibrosis and Reversal of Cirrhosis in Rats by Galectin Inhibitors in Thioacetamide-Induced Liver Disease. PLOS ONE 8(10): e75361. doi:10.1371/journal.pone.0075361
Download PDF >

Traber PG, Zomer E (2013) Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors. PLOS ONE 8(12): e83481. doi:10.1371/journal.pone.0083481
Download PDF >

Posters on NASH Cirrhosis

Boudes P, Zomer E, Shlevin H (2021, November 12-15). Mechanism of galectin-3 binding by belapectin, a galectin-3 inhibitor developed for NASH cirrhosis [Poster presentation]. The Liver Meeting™ 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), held virtually.
Download PDF >

Boudes P, Lomeli B, Zomer E, Harrison S, Rondon J, Lawitz E (2021, November 12-15). Pharmacokinetic exposure and safety of belapectin, a candidate treatment for NASH-cirrhosis, in patients with hepatic insufficiency [Poster presentation]. The Liver Meeting™ 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), held virtually. Download PDF >

Boudes P, Harrison S, Chalasani N (2021, November 12-15). Innovating in cirrhosis: NAVIGATE, a seamless, adaptive, phase 2b/3 of belapectin, a galectin-3 inhibitor, for the prevention of esophageal varices in NASH cirrhosis [Poster presentation]. The Liver Meeting™ 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), held virtually.
Download PDF >

Boudes P, Schattenberg J, Lawitz E (2021, November 12-15). Distribution of the AST/ALT (de Ritis) ratio in a cohort of patients with NASH cirrhosis and portal hypertension and correlation with portal pressure [Poster presentation]. The Liver Meeting™ 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), held virtually.
Download PDF >

Mladenovic A, Vuppalanchi R, Boudes P, Shlevin H, Harrison S, Chalasani N, Desai A (2021, November 12-15). Features of portal hypertension predict health related quality of life over time in NASH cirrhosis [Poster presentation]. The Liver Meeting™ 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), held virtually.
View JGP >

Noureddin M, Goodman Z, Tai D, Ren Y, Boudes P, Chng E, Shlevin H, Harrison S, Chalasani N (2021, November 12-15). Development of machine learning histological scores that correlated with portal pressures and development of varices in NASH patients with cirrhosis [Poster presentation]. The Liver Meeting™ 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), held virtually.
View JPG >

Publications on Oncology

Curti BD, Koguchi Y, Leidner RS, Rolig AS, Sturgill ER, Sun Z, Wu Y, Rajamanickam V, Bernard B, Hilgart-Martiszus I, Fountain CB, Morris G, Iwamoto N, Shimada T, Chang S, Traber PG, Zomer E, Horton R, Shlevin HH, Redmond WL (2021) Enhancing Clinical and Immunological Effects of anti-PD-1 with Belapectin, a Galectin-3 Inhibitor. Journal for ImmunoTherapy of Cancer (JITC) 2021;9:e002371. doi.org/10.1136/jitc-2021-002371
Download PDF >

Sturgill ER, Rolig AS, Linch SN, Mick C, Kasiewicz MJ, Sun Z, Traber PG, Shlevin HH, Redmond WL (2021) Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity. OncoImmunology 10:1. doi.org/10.1080/2162402X.2021.1892265
Download PDF >

Posters on Oncology

Linch S, Kasiewicz M, McNamara M, Hilgart I, Farhad M, Redmond W (2015, November 4-8). Galectin-3 inhibition using novel inhibitor GR-MD02 improves survival and immune function while reducing tumor vasculature [Poster presentation]. The 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015), National Harbor, MD. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P306. http://www.immunotherapyofcancer.org/content/3/S2/P306
Download PDF >